DK1265862T3 - 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse - Google Patents

2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse

Info

Publication number
DK1265862T3
DK1265862T3 DK01925354T DK01925354T DK1265862T3 DK 1265862 T3 DK1265862 T3 DK 1265862T3 DK 01925354 T DK01925354 T DK 01925354T DK 01925354 T DK01925354 T DK 01925354T DK 1265862 T3 DK1265862 T3 DK 1265862T3
Authority
DK
Denmark
Prior art keywords
sup
oxo
pyrrolidine derivatives
processes
preparation
Prior art date
Application number
DK01925354T
Other languages
Danish (da)
English (en)
Inventor
Edmond Differding
Benoit Kenda
Benedicte Lallemand
Alain Matagne
Philippe Michel
Patrick Pasau
Patrice Talaga
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1265862(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa filed Critical Ucb Sa
Application granted granted Critical
Publication of DK1265862T3 publication Critical patent/DK1265862T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
DK01925354T 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse DK1265862T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Publications (1)

Publication Number Publication Date
DK1265862T3 true DK1265862T3 (da) 2006-01-30

Family

ID=9886259

Family Applications (3)

Application Number Title Priority Date Filing Date
DK01925354T DK1265862T3 (da) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse
DK04007733T DK1447399T3 (da) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser
DK04007878.4T DK1452524T3 (da) 2000-02-23 2001-02-21 "2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser"

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK04007733T DK1447399T3 (da) 2000-02-23 2001-02-21 2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser
DK04007878.4T DK1452524T3 (da) 2000-02-23 2001-02-21 "2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser"

Country Status (43)

Country Link
US (12) US6713635B2 (fr)
EP (8) EP1265862B1 (fr)
JP (5) JP4121744B2 (fr)
KR (4) KR100816185B1 (fr)
CN (5) CN1208319C (fr)
AT (5) ATE488500T1 (fr)
AU (5) AU5214401A (fr)
BE (1) BE2016C012I2 (fr)
BG (4) BG65923B1 (fr)
BR (2) BRPI0108664B8 (fr)
CA (2) CA2401033C (fr)
CO (2) CO5271667A1 (fr)
CU (2) CU23293B7 (fr)
CY (3) CY1105517T1 (fr)
CZ (3) CZ20022849A3 (fr)
DE (5) DE60143493D1 (fr)
DK (3) DK1265862T3 (fr)
EG (1) EG24375A (fr)
ES (5) ES2248307T3 (fr)
FR (1) FR16C1001I2 (fr)
GB (1) GB0004297D0 (fr)
HK (2) HK1052695B (fr)
HU (4) HU230270B1 (fr)
IL (5) IL150757A0 (fr)
IS (8) IS2119B (fr)
LT (1) LTC1265862I2 (fr)
LU (1) LU92993I2 (fr)
ME (1) ME00595B (fr)
MX (2) MXPA02008056A (fr)
MY (4) MY127149A (fr)
NL (1) NL300815I2 (fr)
NO (6) NO324485B1 (fr)
NZ (1) NZ520448A (fr)
PL (3) PL212197B1 (fr)
PT (2) PT1447399E (fr)
RO (2) RO121559B1 (fr)
RS (2) RS50455B (fr)
RU (5) RU2291860C3 (fr)
SA (2) SA01220027B1 (fr)
SI (1) SI1265862T1 (fr)
TW (2) TW200626545A (fr)
WO (2) WO2001064637A1 (fr)
ZA (2) ZA200205671B (fr)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
JP4334344B2 (ja) * 2001-08-10 2009-09-30 ユセベ ファルマ ソシエテ アノニム オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用
AU2002340971B2 (en) * 2001-10-08 2007-04-26 Ucb Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
CN1604776A (zh) 2001-10-16 2005-04-06 记忆药物公司 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
WO2003094913A1 (fr) * 2002-05-14 2003-11-20 Ucb, S.A. Utilisation de derives de 2-oxo-1-pyrrolidone pour la preparation d'un medicament
CN1735459A (zh) * 2003-01-13 2006-02-15 Ucb公司 氢化催化剂
CA2515090A1 (fr) * 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd Procede de production de levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
US20050143445A1 (en) * 2003-03-18 2005-06-30 Parthasaradhi Reddy B. Novel crystalline forms of levetiracetam
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
EP1613590A2 (fr) 2003-04-16 2006-01-11 Memory Pharmaceutical Corporation Composés dérivés de 4-(phényl, 3-4-disubstitué)-pyrrolidin-2-one comme inhibiteurs de la phosphodiesterase 4
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1663968A1 (fr) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Procede de preparation de levetiracetam pur
KR101124098B1 (ko) * 2003-09-24 2012-03-21 유씨비 파마, 에스.에이. 2-옥소-1-피롤리딘 유도체를 제조하는 방법
EA010031B1 (ru) 2003-12-02 2008-06-30 Юсб, С.А. Производные имидазола, способы их получения и применения
WO2005121082A1 (fr) * 2004-06-11 2005-12-22 Ucb, S.A. Processus de preparation de derives 2-oxo-1-pyrrolidine par allylation intramoleculaire
MXPA06014228A (es) * 2004-06-21 2007-02-14 Warner Lambert Co Preparacion de pregabalina y compuestos relacionados.
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1802615A1 (fr) * 2004-10-20 2007-07-04 Memory Pharmaceuticals Corporation Inhibiteurs de la phosphodiéstérase 4
CA2488325C (fr) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Methode de synthese amelioree du (s)-alpha-ethyl-2-oxo-1-pyrrolidine-acetamide et du (r)-alpha-ethyl-2-oxo-1-pyrroldine-acetamide
EP2308870A3 (fr) 2005-06-01 2011-10-19 UCB Pharma S.A. Dérivés de 2-oxo-1-pyrrolidine, leurs procédés de préparation et leurs utilisations
EP1731149A1 (fr) * 2005-06-08 2006-12-13 Ucb S.A. Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
WO2007031263A1 (fr) * 2005-09-15 2007-03-22 Ucb Pharma, S.A. Pyrrolidine-2-ones 4-substituees et leur utilisation
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
JP2009518335A (ja) * 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム ３−カルボキシ−２−オキソ−１−ピロリジン誘導体及びそれらの使用
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
ES2444009T3 (es) * 2006-06-08 2014-02-21 Ucb Pharma, S.A. Co-cristales de pirrolidinonas
EA019757B1 (ru) * 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
WO2008021666A2 (fr) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Compositions stables de lévétiracétam et procédés
DK2076508T3 (da) * 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
WO2008103319A2 (fr) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Composés et procédés destinés à être utilisés dans la détection de la gabapentine
WO2008132142A2 (fr) * 2007-04-27 2008-11-06 Ucb Pharma S.A. Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
MX2010009222A (es) * 2008-03-03 2010-09-28 Ucb Pharma Sa Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (fr) 2008-07-24 2010-01-27 ZaCh System S.p.A. Procédé de préparation de lévétiracetam
JP4644881B2 (ja) 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
DK3260118T3 (da) 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP2349335B1 (fr) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Immunodosages du lévétiracétam
WO2010054009A1 (fr) * 2008-11-07 2010-05-14 Novabay Pharmaceuticals, Inc. Compositions antimicrobiennes d'oxazolidinone, d'hydantoïne et d'imidazolidinone
CN102215828A (zh) * 2008-11-18 2011-10-12 Ucb医药有限公司 包含2-氧代-1-吡咯烷衍生物的延长释放制剂
AU2009317280B2 (en) * 2008-11-18 2014-03-06 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
EP2393483B1 (fr) 2009-02-09 2017-06-28 UCB Biopharma SPRL Compositions pharmaceutiques comportant du brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
WO2011015349A2 (fr) 2009-08-07 2011-02-10 Ucb Pharma, S.A. Méthodes d’amélioration de la fonction cognitive
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
CA2778194C (fr) * 2009-10-23 2016-07-12 Ucb Pharma, S.A. Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
EP3034079B1 (fr) 2010-11-15 2018-01-10 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
US8957218B2 (en) 2011-04-18 2015-02-17 Ucb Pharma S.A. 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
JP6162125B2 (ja) 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
MX353024B (es) * 2011-12-27 2017-12-18 Bio Pharm Solutions Co Ltd Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
US9163055B2 (en) 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
WO2014087367A2 (fr) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
EP2945942B1 (fr) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Immunodosages de viroconazole
US9920136B2 (en) 2013-02-13 2018-03-20 Ark Diagnostics, Inc. Posaconazole immunoassays
EA034135B9 (ru) 2013-03-13 2020-04-10 Тафтс Юниверсити Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (fr) 2014-11-10 2016-05-19 Sandoz Ag Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
US20180021307A1 (en) 2015-02-20 2018-01-25 Ucb Biopharma Sprl Combination Treatment
WO2016191435A1 (fr) * 2015-05-25 2016-12-01 Peng Wang Procédés de production du brivaracetam
CN106279074B (zh) * 2015-05-25 2018-06-26 苏州鹏旭医药科技有限公司 一种化合物及其制备方法和在合成布瓦西坦中的用途
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
ES2893301T3 (es) 2015-11-03 2022-02-08 Ucb Biopharma Sprl Proceso para preparar brivaracetam
WO2017076737A1 (fr) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Procédé continu de préparation de brivaracétam
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
EP3452447A4 (fr) 2016-05-03 2019-12-18 The Regents of The University of California Inhibiteurs de synthèse de protéines médiée par des ires
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3571183B1 (fr) 2017-01-20 2024-03-06 The Regents of the University of California Dérivés de 3-(phényl)-2-(aminométhyl)-1-phényl-2-propén-1-one en tant qu'inhibiteurs du domaine n-terminal du récepteur androgène pour le traitement du cancer de la prostate
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
WO2018141276A1 (fr) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 Forme cristalline a de l'intermédiaire de brivaracétam et son procédé de préparation, forme cristalline c de brivaracétam et son procédé de préparation
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
KR102642823B1 (ko) 2017-06-30 2024-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
CN111868039A (zh) 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
WO2019152536A1 (fr) 2018-01-30 2019-08-08 The Regents Of The University Of California Inhibiteurs de la voie wnt/bêta-caténine
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (fr) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Procédé pour la nucléation de cristaux dans un tube capillaire à partir d'une solution
CA3097818A1 (fr) 2018-05-08 2019-11-14 UCB Biopharma SRL Derives de 1-imidazothiadiazolo-2h-pyrrol-5-one
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110615744B (zh) 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
EP3813841B1 (fr) 2018-06-29 2025-08-13 The Regents Of The University Of California Nouvelles pinces moléculaires contre des troubles neurologiques et des infections virales
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
BR112021001499A2 (pt) 2018-07-27 2021-04-27 California Institute Of Technology inibidores de cdk e usos dos mesmos
DK3867223T3 (da) 2018-10-17 2026-03-16 Univ California Prodrugs af alpha-ketoglutarat, alpha-ketobutyrat, alpha-ketoisovalerat og alpha-ketoisohexanoat og anvendelser deraf
EP3699173A1 (fr) 2018-10-18 2020-08-26 California Institute of Technology Pyrrolidines, pipérazines et diazépanes disubstitués par gem, compositions et leurs procédés de fabrication
KR20210068591A (ko) 2018-10-31 2021-06-09 주식회사 인투셀 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도
SG11202105863PA (en) 2018-12-04 2021-07-29 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
EP3944739A4 (fr) 2019-02-25 2023-06-21 The Regents of the University of California Procédés de fragmentation de liaison carbone-carbone
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
EP3947387B1 (fr) 2019-03-25 2024-10-23 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
CN114286675A (zh) 2019-06-04 2022-04-05 海格生物科学有限责任公司 作为食欲肽拮抗剂的咪唑衍生物、组合物以及方法
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
AU2020407122A1 (en) 2019-12-20 2022-06-23 The Regents Of The University Of California Synthesis of compounds to promote hair growth
WO2021142132A1 (fr) 2020-01-07 2021-07-15 The Trustees Of Princeton University Compositions et procédés pour le traitement d'une maladie par manipulation du métabolisme de la sérine
WO2021142221A1 (fr) 2020-01-10 2021-07-15 The Regents Of The University Of California Compositions et méthodes de traitement de maladies neurodégénératives
US20230174460A1 (en) 2020-04-21 2023-06-08 President And Fellowes Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) * 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
WO2022035805A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. 1,2,4-oxadiazoles substitués utilisés en tant qu'inhibiteurs de petites molécules de la protéase 28 spécifique de l'ubiquitine
CA3191163A1 (fr) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Inhibiteurs a petites molecules pyrimidine-thieno-pyridine tricycliques fusionnees de la protease 28 specifique de l'ubiquitine
US20230271918A1 (en) 2020-08-10 2023-08-31 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
CN116782894A (zh) * 2020-10-06 2023-09-19 D.E.肖研究有限责任公司 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物
EP4232161A1 (fr) 2020-10-23 2023-08-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs covalents de créatine kinase (ck) et leurs utilisations dans le traitement et la prévention du cancer
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
AU2021409394A1 (en) 2020-12-21 2023-07-27 Cornell University Peptide-linked drug delivery system
WO2022150574A1 (fr) 2021-01-08 2022-07-14 Cornell University Inhibiteurs de la lipoamide déshydrogénase de mycobacterium tuberculosis
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US12559456B2 (en) 2021-02-03 2026-02-24 Suzhou Brighthope Pharma Tech Co., Ltd Method for preparing levetiracetam and intermediates thereof
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (fr) 2022-06-24 2023-12-28 Cornell University Inhibiteurs de mycobacterium tuberculosis lipoamide déshydrogénase
CN119604494A (zh) 2022-07-13 2025-03-11 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
US20260076939A1 (en) * 2022-08-31 2026-03-19 Korea University Research And Business Foundation Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor
WO2024163711A1 (fr) 2023-02-02 2024-08-08 Osmoses Inc. Membranes composites polymères en échelle de norbornyl benzocyclobutène pour la séparation de fluides
CN116041240B (zh) 2023-02-17 2024-04-09 扬州奥锐特药业有限公司 布立西坦中间体的不对称催化氢化合成方法
EP4431086A1 (fr) 2023-03-16 2024-09-18 Adalvo Limited Composition pharmaceutique comprenant du (2s)-2--[(4r)-2-oxo-4-propyltétrahydro-1h-pyrrol-1-yl!butanamide
US12590059B2 (en) 2023-03-28 2026-03-31 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam
WO2025078883A2 (fr) 2023-05-06 2025-04-17 Prepaire Labs Limited Composé organique (oxime) pour lutter contre des agents chimiques de guerre
US12528770B2 (en) 2023-06-12 2026-01-20 Suzhou Brighthope Pharmatech Co., Ltd. Process for the production of levetiracetam and intermediates thereof
AU2024344058A1 (en) 2023-09-18 2026-04-02 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025072893A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'administration de gènes non viraux
WO2025106670A1 (fr) 2023-11-14 2025-05-22 Flagship Pioneering Innovations Vii, Llc Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques
WO2025231452A1 (fr) 2024-05-02 2025-11-06 Martinez Montemayor Michelle Dérivés de peroxyde d'ergostérol et leurs utilisations
WO2026030679A1 (fr) 2024-08-01 2026-02-05 Osmoses Inc. Membranes polymères à fibres creuses pour séparation de fluide
WO2026060616A1 (fr) 2024-09-20 2026-03-26 Fulcrum Therapeutics, Inc. Inhibiteurs de phénothiazine et de phénoxazine calmoduline et leurs procédés d'utilisation
US20260090998A1 (en) 2024-10-02 2026-04-02 Battelle Memorial Institute Methods of using polymer nanoparticle compositions for treating a disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD92031A (fr)
DE92031C (fr) *
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
SU731892A3 (ru) 1974-10-15 1980-04-30 Монсанто Компани (Фирма) Способ получени оптических изомеров -замещенных -ациламидопропионовых кислот
EP0089901B1 (fr) * 1982-03-24 1987-05-13 Prodes S.A. Esters de l'acide 2-oxo-1-pyrrolidineacétique, procédés de préparation et compositions thérapeutiques les contenant
EP0089900B1 (fr) * 1982-03-24 1985-12-27 Prodes S.A. N-((2-oxo-1-pyrrolidinyl)acétyl)pipérazines, procédés pour leur préparation et leurs sels, ainsi que leur utilisation dans des préparations pharmaceutiques
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2067614C (fr) * 1991-05-02 2002-07-30 Eiichi Otomo Agent pour le traitement de la demence
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP0645135A1 (fr) * 1993-09-29 1995-03-29 Solco Basel AG Composition antisolaire contenant du hémodialysate
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) * 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
CA2475026A1 (fr) 1999-12-01 2001-06-07 Ucb, S.A. Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Also Published As

Publication number Publication date
HU230270B1 (hu) 2015-11-30
AU2005200717A1 (en) 2005-03-17
NO2016005I2 (no) 2016-03-08
DE60113514D1 (de) 2005-10-27
HUS1600017I1 (hu) 2020-02-28
NL300815I2 (fr) 2016-07-27
RO121559B1 (ro) 2007-11-30
AU2005200718A1 (en) 2005-03-17
IS2754B (is) 2011-09-15
HUP0300196A2 (hu) 2003-06-28
CO5271667A1 (es) 2003-04-30
BG109297A (en) 2006-06-30
CN1680314A (zh) 2005-10-12
AU778510B2 (en) 2004-12-09
IL166768A (en) 2010-04-15
KR20020075927A (ko) 2002-10-07
NO20053644L (no) 2002-10-22
NO2023025I1 (no) 2023-06-20
MY140593A (en) 2009-12-31
EP1577295A1 (fr) 2005-09-21
HK1052695A1 (en) 2003-09-26
DE60140222D1 (de) 2009-11-26
IS6472A (is) 2002-07-16
CY2016022I2 (el) 2016-10-05
RU2006125756A (ru) 2008-01-27
EP1452524B1 (fr) 2009-10-14
PT1452524E (pt) 2010-01-18
ATE445597T1 (de) 2009-10-15
EP1265862B1 (fr) 2005-09-21
RS50455B (sr) 2010-03-02
AU2005200718B2 (en) 2007-05-24
CN1740150A (zh) 2006-03-01
CY2016022I1 (el) 2016-10-05
MXPA02008206A (es) 2004-04-05
US20030040631A1 (en) 2003-02-27
IS2119B (is) 2006-06-15
ATE325093T1 (de) 2006-06-15
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
US7217826B2 (en) 2007-05-15
US6784197B2 (en) 2004-08-31
IS6481A (is) 2002-07-23
AU2005200717B2 (en) 2007-05-17
IL150757A0 (en) 2003-02-12
JP4121744B2 (ja) 2008-07-23
NO20023997D0 (no) 2002-08-22
WO2001062726A2 (fr) 2001-08-30
MEP6109A (en) 2011-12-20
RU2291860C2 (ru) 2007-01-20
US6806287B2 (en) 2004-10-19
IS7922A (is) 2005-06-29
ME00595B (fr) 2011-12-20
NO20023997L (no) 2002-10-22
MY138966A (en) 2009-08-28
RO121597B1 (ro) 2007-12-28
AU7389601A (en) 2001-09-12
NO20023995L (no) 2002-10-21
RU2292336C2 (ru) 2007-01-27
ZA200205671B (en) 2003-11-10
NO324051B1 (no) 2007-08-06
US20120035239A1 (en) 2012-02-09
ES2248307T3 (es) 2006-03-16
US20050171188A1 (en) 2005-08-04
IS7919A (is) 2005-06-29
JP2006022107A (ja) 2006-01-26
JP4938259B2 (ja) 2012-05-23
CZ304420B6 (cs) 2014-04-30
CZ20022850A3 (cs) 2003-02-12
EP1604979A1 (fr) 2005-12-14
ZA200205837B (en) 2003-11-04
RS50454B (sr) 2010-03-02
LTPA2016013I1 (lt) 2016-05-25
ATE282592T1 (de) 2004-12-15
AU2001252144B2 (en) 2005-04-28
EP1265862A2 (fr) 2002-12-18
NO2016005I1 (no) 2016-03-08
CZ20022849A3 (cs) 2003-02-12
EP1447399B1 (fr) 2006-05-03
EP1263727A1 (fr) 2002-12-11
WO2001062726A3 (fr) 2002-01-17
US20050159475A1 (en) 2005-07-21
SA01220027B1 (ar) 2006-09-19
AU5214401A (en) 2001-09-03
BG107016A (en) 2003-04-30
HU0500902D0 (en) 2005-12-28
BG65803B1 (bg) 2009-12-31
KR100816185B1 (ko) 2008-03-21
HUP0300196A3 (en) 2005-10-28
BG65923B1 (bg) 2010-05-31
GB0004297D0 (en) 2000-04-12
JP2007182459A (ja) 2007-07-19
JP2003523996A (ja) 2003-08-12
US8034958B2 (en) 2011-10-11
CN1740151A (zh) 2006-03-01
IL150842A0 (en) 2003-02-12
CN1208319C (zh) 2005-06-29
US6713635B2 (en) 2004-03-30
MY139420A (en) 2009-09-30
US7692028B2 (en) 2010-04-06
CN1303066C (zh) 2007-03-07
CA2401033A1 (fr) 2001-08-30
BG65783B1 (bg) 2009-11-30
BR0108657A (pt) 2003-04-29
US6858740B2 (en) 2005-02-22
PL210121B1 (pl) 2011-12-30
RU2005125645A (ru) 2007-02-20
US7358276B2 (en) 2008-04-15
NO20053645L (no) 2002-10-22
DE60113514T2 (de) 2006-05-18
CN1179944C (zh) 2004-12-15
EP1447399A1 (fr) 2004-08-18
RU2355680C2 (ru) 2009-05-20
PL212197B1 (pl) 2012-08-31
DE60107216T2 (de) 2005-11-03
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
EP1577296A1 (fr) 2005-09-21
DE60119397T2 (de) 2007-04-19
RU2291860C3 (ru) 2017-11-16
BR0108664A (pt) 2003-04-29
CA2401033C (fr) 2008-07-29
IS2176B (is) 2006-12-15
EP1477478B1 (fr) 2010-11-17
EP1263727B1 (fr) 2004-11-17
DE60143493D1 (de) 2010-12-30
US20040192757A1 (en) 2004-09-30
KR100759145B1 (ko) 2007-09-14
US20080097109A1 (en) 2008-04-24
CY1109718T1 (el) 2014-08-13
IL150842A (en) 2008-06-05
PL359388A1 (en) 2004-08-23
WO2001064637A1 (fr) 2001-09-07
YU63202A (sh) 2005-09-19
JP2003528828A (ja) 2003-09-30
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
ES2231501T3 (es) 2005-05-16
JP2006022108A (ja) 2006-01-26
EP1452524A1 (fr) 2004-09-01
BRPI0108664B8 (pt) 2021-05-25
HK1052516B (zh) 2006-02-10
EP1447399B9 (fr) 2006-10-18
IS7921A (is) 2005-06-29
FR16C1001I1 (fr) 2016-07-01
MY127149A (en) 2006-11-30
MXPA02008056A (es) 2004-08-12
KR20050090090A (ko) 2005-09-12
PL365159A1 (en) 2004-12-27
RU2002124865A (ru) 2004-01-10
DE60107216D1 (de) 2004-12-23
CA2401048A1 (fr) 2001-09-07
DE60119397D1 (de) 2006-06-08
EP1477478A3 (fr) 2004-11-24
KR100720784B1 (ko) 2007-05-23
DK1447399T3 (da) 2006-08-28
IS7923A (is) 2005-06-29
US6911461B2 (en) 2005-06-28
US8492416B2 (en) 2013-07-23
US20050171187A1 (en) 2005-08-04
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
IS7920A (is) 2005-06-29
KR100681580B1 (ko) 2007-02-09
NO20023995D0 (no) 2002-08-22
ATE304999T1 (de) 2005-10-15
JP4769756B2 (ja) 2011-09-07
CY1105517T1 (el) 2010-07-28
YU63102A (sh) 2005-09-19
ES2334998T3 (es) 2010-03-18
US20030120080A1 (en) 2003-06-26
CZ304702B6 (cs) 2014-09-03
ES2264060T3 (es) 2006-12-16
CA2401048C (fr) 2009-01-20
CN1404470A (zh) 2003-03-19
IL170181A (en) 2010-11-30
NO324485B1 (no) 2007-10-29
HUP0204526A2 (hu) 2003-04-28
LTC1265862I2 (lt) 2023-09-11
SA01220078B1 (ar) 2006-10-29
US20100222576A1 (en) 2010-09-02
CN1404469A (zh) 2003-03-19
TW200626544A (en) 2006-08-01
ATE488500T1 (de) 2010-12-15
CO5280059A1 (es) 2003-05-30
CU23293B7 (es) 2008-06-30
IL166768A0 (en) 2006-01-15
KR20020075926A (ko) 2002-10-07
CU23201A3 (es) 2007-04-06
FR16C1001I2 (fr) 2017-02-03
EP1477478A2 (fr) 2004-11-17
KR20050091112A (ko) 2005-09-14
LU92993I2 (fr) 2016-05-11
US20040092576A1 (en) 2004-05-13
BE2016C012I2 (fr) 2020-01-30
JP4081275B2 (ja) 2008-04-23
US20040116507A1 (en) 2004-06-17
IS7918A (is) 2005-06-29
BRPI0108664B1 (pt) 2016-07-26
ES2355140T3 (es) 2011-03-23
HUP0204526A3 (en) 2005-03-29
PL213669B1 (pl) 2013-04-30
RU2005125569A (ru) 2007-02-20
DK1452524T3 (da) 2010-03-01
HU229514B1 (en) 2014-01-28
US6969770B2 (en) 2005-11-29
EG24375A (en) 2009-03-19
SI1265862T1 (sl) 2006-02-28

Similar Documents

Publication Publication Date Title
DK1265862T3 (da) 2-oxo-1-pyrrolidinderivater, fremgangsmåder til fremstilling heraf og deres anvendelse